NeuPath Health Inc

NeuPath Health Inc operates with a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.13, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not with a large buffer. Free cash flow stands at 190,000 CAD, which is a positive sign for operational efficiency and the ability to fund growth initiatives or return value to shareholders.

Profitability metrics for NeuPath Health Inc are mixed. The company reported a net loss of 378,000 CAD, and its return on equity (ROE) is negative at -1.74%, indicating that the company is not generating returns for its shareholders. Similarly, the return on assets (ROA) is -0.91%, suggesting that the company is not effectively utilizing its assets to generate profit. These figures are below the industry median for healthcare facilities and services, highlighting a need for operational improvements.

Geographically and segment-wise, NeuPath Health Inc's revenue concentration is not disclosed in the available data. However, the company's primary business activity is in the biotechnology segment, which is a high-growth area within the healthcare sector. The lack of detailed segment and geographic breakdown limits the ability to assess diversification risks and opportunities.

Looking at the growth trajectory, NeuPath Health Inc has reported a revenue of 17,486,000 CAD. While the company is not currently profitable, the positive free cash flow and the presence of a net loss that is narrowing from previous periods suggest potential for future growth. The company's capital expenditure of -47,000 CAD indicates a reduction in investment in physical assets, which could be a strategic move to preserve cash or a sign of operational scaling back.

Risk factors for NeuPath Health Inc include a medium liquidity risk, as indicated by the risk assessment. The company's net cash position is negative after accounting for total debt, which could pose challenges in meeting short-term obligations. The dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's negative net income and operating income suggest financial instability, which could affect its ability to sustain operations without additional financing.

Recent events and filings for NeuPath Health Inc do not show any significant developments that would impact the company's financial position or strategic direction. The company's analyst estimates indicate a mean price target of 0.77 CAD, with a median price target of 0.77 CAD. The mean recommendation from analysts is 2.00, which is a "Buy" rating, suggesting that the market has a cautiously optimistic view of the company's prospects.

Revenue grew 16.2% year-over-year to CAD 72.8 million, demonstrating strong top-line expansion momentum.

Operating income turned positive at CAD 692,000, marking a significant 116.9% improvement from prior periods.

Analysts project 25.4% upside to a mean price target of CAD 0.765, signaling market confidence.

Free cash flow surged 126.3% to CAD 864,000, indicating improved operational efficiency and cash generation.

Long-term debt decreased to CAD 11.3 million, reflecting a prudent approach to balance sheet management.

The company faces high credit risk, posing significant potential challenges for financial stability and borrowing costs.

Net margin of -2.2% remains well below the healthcare cohort median of 4.2%, indicating persistent profitability issues.

Return on equity is negative at -1.7%, underperforming the cohort median of 4.6% significantly.

Cash conversion ratio sits in the bottom quartile at -0.23, far trailing the cohort median of 1.35.

Medium liquidity risk flags suggest potential difficulties in meeting short-term financial obligations efficiently.

Revenue C$22.1M, +17,3% YoY; Operating income −272,3% YoY.

• ▍Revenue C$22.1M, +17,3% YoY
• ▍Operating income −272,3% YoY
• ▍Net income −66,9% YoY
• ▍Free cash flow −111,5% YoY
• ▍Net margin -1.8%

Revenue C$22.1M, +25,8% YoY; Operating income +896,5% YoY.

• ▍Revenue C$22.1M, +25,8% YoY
• ▍Operating income +896,5% YoY
• ▍Net income +61,9% YoY
• ▍Free cash flow −54,0% YoY
• ▍Net margin -0.7%

Revenue C$23.6M, +25,2% YoY; Operating income +1,6% YoY.

• ▍Revenue C$23.6M, +25,2% YoY
• ▍Operating income +1,6% YoY
• ▍Net income −12,8% YoY
• ▍Free cash flow +58,6% YoY
• ▍Net margin 1.1%

Revenue C$87.2M, +19,8% YoY; Operating income +21,1% YoY.

• ▍Revenue C$87.2M, +19,8% YoY
• ▍Operating income +21,1% YoY
• ▍Net income +1,5% YoY
• ▍Free cash flow +17,5% YoY
• ▍Net margin -0.8%

Revenue C$66.1M, +5,5% YoY; Operating income +82,7% YoY.

• ▍Revenue C$66.1M, +5,5% YoY
• ▍Operating income +82,7% YoY
• ▍Net income +97,4% YoY
• ▍Free cash flow +162,7% YoY
• ▍Net margin -0.2%

Revenue C$60.9M; Operating income -C$3.3M.

• ▍Revenue C$60.9M
• ▍Operating income -C$3.3M
• ▍Net margin -5.3%